- Condition: Myelodysplastic Syndrome (MDS)
Intervention: Drug: Azacitidine
Sponsors: Celgene Corporation; Celgene Corporation; PRA International
Not yet recruiting - verified May 2012 - Condition: Anemia in Chronic Kidney Disease
Interventions: Drug: FG-4592; Drug: Placebo
Sponsors: FibroGen; FibroGen
Recruiting - verified May 2012 - Condition: Anemia in End Stage Renal Disease
Interventions: Drug: FG-4592; Drug: Epoetin Alfa
Sponsors: FibroGen; FibroGen; Ruijin Hospital; RenJi Hospital; Chang Zheng Hospital; XinHua Hospital; Peking University First Hospital; First Affiliated Hospital, Sun Yat-Sen University; Zhejiang University No 1. Hospital; Peking Union Medical College Hospital; Shenzhen People's Hospital
Recruiting - verified May 2012 - Condition: Irregular Antibody Screening
Intervention:
Sponsors: Johnson & Johnson Medical, China; Johnson & Johnson Medical, China
Not yet recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Drug: Placebo and prednisone; Drug: Abiraterone acetate and prednisone
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012 - Condition: Colorectal Neoplasms
Interventions: Drug: Regorafenib (BAY73-4506); Drug: Placebo
Sponsors: Bayer; Bayer
Not yet recruiting - verified April 2012 - Condition: Metastatic Breast Cancer
Interventions: Drug: Capecitabine; Drug: Etoposide
Sponsors: Peking University; Tao OUYANG
Not yet recruiting - verified May 2012 - Condition: Uterine Fibroids
Intervention: Device: MR-HIFU uterine fibroid treatment
Sponsors: Philips Healthcare; Philips Healthcare
Not yet recruiting - verified April 2012 - Condition: Hepatitis C
Intervention:
Sponsors: Johnson & Johnson Medical, China; Johnson & Johnson Medical, China
Recruiting - verified April 2012 - Condition: Kidney Failure, Chronic
Interventions: Drug: iodixanol; Drug: iopromide
Sponsors: Peking University First Hospital; Yong Huo
Not yet recruiting - verified April 2012 - Condition: Rectal Cancer
Intervention: Drug: Amifostine
Sponsors: Chinese Academy of Medical Sciences; Chinese Academy of Medical Sciences
Recruiting - verified April 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Vildagliptin; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Rectal Neoplasms
Interventions: Drug: capecitabine; Drug: Capecitabine; Drug: Capecitabine; Drug: Capecitabine; Drug: Capecitabine
Sponsors: Chinese Academy of Medical Sciences; Chinese Academy of Medical Sciences
Recruiting - verified April 2012 - Condition: Rectal Cancer
Intervention:
Sponsors: Chinese Academy of Medical Sciences; Chinese Academy of Medical Sciences
Recruiting - verified April 2012 - Condition: Acute Lung Injury
Interventions: Procedure: noninvasive positive pressure ventilation; Procedure: oxygen therapy
Sponsors: Beijing Hospital; Beijing Hospital
Not yet recruiting - verified April 2012 - Condition: Heroin Addiction
Interventions: Drug: JITAI Combined with psychological intervention; Drug: Methadone; Drug: Traditional Chinese Medicine JITAI
Sponsors: Shanghai Mental Health Center; Shanghai Mental Health Center; Shanghai Center of Biomedicine Development
Recruiting - verified April 2012 - Condition: Liver Cirrhosis
Interventions: Biological: mesenchymal stem cells; Biological: Conventional therapy
Sponsors: Alliancells Bioscience Corporation Limited; Alliancells Bioscience Corporation Limited
Not yet recruiting - verified April 2012 - Condition: Gastric Adenocarcinoma
Interventions: Drug: Oxaliplatin+S-1; Drug: Adjuvant Oxaliplatin/S-1（SOX）
Sponsors: Chinese PLA General Hospital; Lin Chen
Recruiting - verified April 2012 - Condition: Hepatitis C
Intervention:
Sponsors: Peking University People's Hospital; Peking University People's Hospital; Bristol-Myers Squibb
Recruiting - verified May 2012 - Condition: Depression
Intervention: Behavioral: reminiscence therapy
Sponsors: Chinese Academy of Sciences; Chinese Academy of Sciences
Recruiting - verified May 2012 - Condition: Ulcerative Colitis
Interventions: Drug: Infliximab; Drug: Placebo
Sponsors: Xian-Janssen Pharmaceutical Ltd.; Xian-Janssen Pharmaceutical Ltd.
Recruiting - verified April 2012 - Condition: Chronic Hepatitis C
Interventions: Drug: Ypeginterferon alfa-2b; Drug: Pegasys; Drug: Ypeginterferon alfa-2b; Drug: Pegasys
Sponsors: Xiamen Amoytop Biotech Co., Ltd.; Xiamen Amoytop Biotech Co., Ltd.
Recruiting - verified April 2012 - Condition: Hypertension
Intervention: Drug: Valsartan
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Hepatocellular Carcinoma
Intervention: Drug: Brivanib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Hip Fracture
Interventions: Drug: celecoxib; Drug: Acetaminophen oxycodone
Sponsors: Beijing Army General Hospital; Beijing Army General Hospital
Recruiting - verified April 2012 - Conditions: Atrial Fibrillation; Myocardium; Injury
Interventions: Drug: Rosuvastatin; Drug: Placebo
Sponsors: University of Oxford; University of Oxford; Cardiovascular Institute & Fuwai Hospital; Chinese Academy of Medical Sciences; Peking Union Medical College
Recruiting - verified May 2012 - Condition: Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)
Interventions: Drug: dalcetrapib; Drug: Placebo; Other: Background care
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Metastatic Colorectal Cancer
Intervention: Drug: CPT-11
Sponsors: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences; The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Recruiting - verified May 2012 - Condition: Asthma
Interventions: Drug: GW685698/GW642444; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Asthma
Interventions: Drug: GW685698/GW642444; Drug: CCI18781
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Complicated Intra-Abdominal Infection
Interventions: Drug: CAZ-AVI; Drug: Metronidazole; Drug: Meropenem
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Recruiting - verified April 2012 - Condition: Metastatic Renal Cell Carcinoma
Intervention: Drug: Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Macular Degeneration
Interventions: Biological: VEGF Trap-Eye (BAY86-5321); Drug: Visudyne
Sponsors: Bayer; Bayer; Regeneron Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: insulin detemir; Drug: insulin aspart; Drug: insulin NPH; Drug: human soluble insulin; Drug: metformin
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Glimepiride and Metformin hydrochloride combination (HOE490); Drug: Glimepiride (HOE490)
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Postherpetic Neuralgia ( PHN )
Interventions: Drug: Lyrica (pregabalin); Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Gastric Cancer
Interventions: Drug: trastuzumab [Herceptin]; Drug: trastuzumab [Herceptin]; Drug: capecitabine; Drug: cisplatin
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium + olodaterol; Drug: tiotropium; Drug: tiotropium; Drug: olodaterol
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Osteoarthritis of the Knee
Interventions: Drug: Meloxicam; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium; Drug: olodaterol; Drug: tiotropium; Drug: tiotropium + olodaterol
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Atrial Fibrillation
Intervention:
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Fracture of Acetabulum
Interventions: Device: Anatomical locking plate; Procedure: The Reconstructive Plate
Sponsors: Chinese PLA General Hospital; Peifu Tang
Recruiting - verified May 2012 - Condition: Intertrochanteric Fracture
Interventions: Device: new type of intramedullary nail; Device: The intramedullary nail of PFNA
Sponsors: Chinese PLA General Hospital; Peifu Tang
Recruiting - verified May 2012 - Conditions: Anxiety; Depression; Alcohol-abuse
Interventions: Other: regular intervention; Other: community intervention
Sponsors: Shanghai Mental Health Center; Shanghai Mental Health Center
Recruiting - verified April 2012 - Condition: Alzheimer's Disease
Interventions: Drug: Rivastigmine; Drug: Rivastigmine
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Fibromyalgia
Interventions: Drug: pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Canagliflozin 100mg; Drug: Canagliflozin 300mg
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2012 - Conditions: Femoral Neck Fractures; Intertrochanteric Fracture
Interventions: Procedure: Gamma3 Intramedullary Nails (Stryker); Procedure: Sliding Hip Screws
Sponsors: Stryker Trauma GmbH; Stryker Trauma GmbH; Stryker Osteosynthesis; Global Research Solutions
Recruiting - verified May 2012 - Condition: Healthy
Interventions: Other: Study formula feeding; Other: Human milk feeding; Other: Mixed feeding
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: placebo; Drug: carboplatin; Drug: paclitaxel
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: vildagliptin; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: erlotinib [Tarceva]; Drug: gemcitabine; Drug: cisplatin
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Pulmonary Fibrosis
Interventions: Drug: placebo; Drug: BIBF 1120
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Lymphoma, B-Cell
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Diabetic Neuropathy, Painful
Interventions: Drug: Pregabalin; Drug: Placebo matched with pregabalin
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Pulmonary Fibrosis
Interventions: Drug: placebo; Drug: BIBF 1120
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: erlotinib [Tarceva]; Drug: Placebo; Drug: erlotinib [Tarceva]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Conditions: Myelodysplastic Syndrome,; Transfusional Iron Overload
Intervention: Drug: Deferasirox
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Colorectal Cancer
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Non-small Cell Lung Cancer
Interventions: Drug: BKM120 or Docetaxel; Drug: BKM120 or Docetaxel or Pemetrexed
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: trastuzumab [Herceptin]; Drug: paclitaxel; Drug: docetaxel
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Sitagliptin 100mg; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Rectal Neoplasms
Interventions: Drug: Capecitabine; Drug: Capecitabine; Drug: Capecitabine; Drug: Capecitabine; Drug: Capecitabine; Drug: Capecitabine; Drug: Capecitabine; Drug: Capecitabine; Drug: Capecitabine
Sponsors: Chinese Academy of Medical Sciences; Chinese Academy of Medical Sciences
Recruiting - verified April 2012 - Condition: HIV-1 Infection
Intervention: Drug: Rilpivirine
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012 - Condition: Bipolar Depression
Interventions: Drug: Quetiapine Fumarate (SEROQUEL) Extended Release; Drug: Placebo
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified May 2012 - Condition: Schizophrenia
Interventions: Drug: RO4917838; Drug: RO4917838; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Conditions: Renal Cell Carcinoma; Cancer
Interventions: Drug: pazopanib; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Conditions: Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug
Interventions: Drug: High Dose GGQL Decoction; Drug: Mild dose GGQL Decoction; Drug: Low dose GGQL Decoction; Drug: Placebo
Sponsors: Guang'anmen Hospital of China Academy of Chinese Medical Sciences; Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Recruiting - verified May 2012 - Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Insulin glargine (HOE901); Drug: NPH insulin
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Hepatocellular Carcinoma
Interventions: Drug: Axitinib (AG-013736); Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: 5-FU（intravenous infusion）+epirubicin+cyclophosphamide; Drug: 5-FU（intravenous bolus）+epirubicin+cyclophosphamide; Drug: epirubicin+cyclophosphamide
Sponsors: Peking University; Tao OUYANG
Recruiting - verified April 2012 - Condition: Schizophrenia
Interventions: Drug: RO4917838; Drug: RO4917838; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Erlotinib [Tarceva]; Drug: Erlotinib [Tarceva]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Breast Neoplasms
Intervention: Drug: Aromasin (exemestane)
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Conditions: Gastric Cancer; Concurrent Chemoradiotherapy
Intervention: Drug: nimotuzumab
Sponsors: Chinese Academy of Medical Sciences; Chinese Academy of Medical Sciences
Recruiting - verified April 2012 - Condition: Primary Myelofibrosis
Interventions: Drug: Pomalidomide; Other: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012 - Condition: Non Squamous Lung Cancer
Interventions: Drug: treatment; Drug: treatment
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Breast Neoplasms
Interventions: Drug: BIBW 2992; Drug: trastuzumab; Drug: vinorelbine; Drug: vinorelbine
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Neoplasms Malignant
Intervention: Drug: Crizotinib
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Epilepsy; Depression
Interventions: Drug: wuling capsule; Drug: placebo of wuling capsule
Sponsors: Shanghai Zhongshan Hospital; Shanghai Zhongshan Hospital; Shanghai Wu Mengchao Medical Foundation; Shanghai Ankang Pharmaceutical Co.,LTD
Recruiting - verified April 2012 - Condition: Carcinoma, Hepatocellular
Interventions: Drug: Brivanib; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Pulmonary Arterial Hypertension
Interventions: Drug: ACT-293987; Drug: Placebo
Sponsors: Actelion; Actelion
Recruiting - verified April 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin; Drug: Dapagliflozin; Drug: Metformin; Drug: Dapagliflozin Placebo; Drug: Pioglitazone
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified February 2012 - Conditions: Candidiasis; Fungemia; Candida
Intervention: Drug: voriconazole
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Hemostasis
Intervention: Drug: UTI & TA
Sponsors: Cardiovascular Institute & Fuwai Hospital; Cardiovascular Institute & Fuwai Hospital
Recruiting - verified May 2012 - Condition: Hemostasis
Intervention: Drug: Tranexamic Acid
Sponsors: Cardiovascular Institute & Fuwai Hospital; Cardiovascular Institute & Fuwai Hospital
Recruiting - verified May 2012 - Condition: Heart Failure With Reduced Ejection Fraction
Interventions: Drug: LCZ696 200 mg BID; Drug: Enalapril 10 mg BID
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Condition: Melanoma
Intervention: Drug: nilotinib (AMN107)
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Primary Breast Cancer
Intervention: Drug: paclitaxel/anthracycline
Sponsors: Peking University; Tao OUYANG; Beijing Municipal Science & Technology Commission; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences; Peking University First Hospital; Peking University People's Hospital; Beijing Chao Yang Hospital; 307 Hospital of PLA
Recruiting - verified April 2012 - Condition: Castleman's Disease
Interventions: Drug: Placebo; Drug: CNTO 328
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2012 - Conditions: HER2/Neu Over-expressing Locally Advanced Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: everolimus, vinorelbine, trastuzumab; Drug: Placebo + vinorelbine + trastuzumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Lymphocytic Leukemia, Chronic
Interventions: Drug: RO5072759; Drug: rituximab; Drug: chlorambucil
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Genentech; German CLL Study Group
Recruiting - verified April 2012 - Condition: Metastatic Colorectal Cancer
Interventions: Drug: Cetuximab (Erbitux); Drug: Panitumumab (Vectibix)
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Tiotropium +salmeterol+ fluticasone high dose; Drug: Tiotropium+salmeterol+ fluticasone high,med, low, placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: PF-02341066
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Hepatitis B, Chronic
Intervention: Drug: peginterferon alfa-2a [Pegasys]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Kidney Neoplasms
Interventions: Drug: Axitinib (AG-013736); Drug: Sorafenib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Conditions: Atrial Fibrillation; Arrhythmia; Stroke Prevention; Mortality
Interventions: Device: Left atrial ablation; Drug: Rate or Rhythm Control Therapy
Sponsors: Mayo Clinic; Mayo Clinic; National Heart, Lung, and Blood Institute (NHLBI); St. Jude Medical; Biosense Webster, Inc.
Recruiting - verified April 2012 - Condition: Acute Coronary Syndrome
Interventions: Drug: Acetylsalicylic acid (Aspirin, BAY 81-8781); Drug: Acetylsalicylic acid (Aspirin, BAY 81-8781); Drug: Acetylsalicylic acid (Aspirin, BAY 81-8781)
Sponsors: Bayer; Bayer
Recruiting - verified April 2012 - Condition: Hepatocellular Carcinoma
Interventions: Drug: Brivanib; Drug: Brivanib Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed (Alimta); Drug: Gefitinib (IRESSA)
Sponsors: Chinese Society of Lung Cancer; Chinese Society of Lung Cancer
Recruiting - verified June 2009 - Condition: Breast Cancer
Interventions: Drug: Everolimus; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Chronic Heart Failure
Interventions: Drug: Enalapril monotherapy; Drug: Aliskiren monotherapy; Drug: Aliskiren / Enalapril combination therapy
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Condition: Chronic Myelogenous Leukemia
Interventions: Drug: nilotinib; Drug: imatinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: RAD001; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Rectal Neoplasms
Intervention:
Sponsors: Chinese Academy of Medical Sciences; Chinese Academy of Medical Sciences; Zhejiang Cancer Hospital
Recruiting - verified April 2012 - Condition: Venous Thrombosis
Interventions: Drug: Enoxaparin; Drug: warfarin; Drug: Placebo for apixaban; Drug: Placebo for enoxaparin; Drug: Placebo for warfarin; Drug: apixaban
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Pfizer
Recruiting - verified October 2010 - Conditions: Mycoses; Candidiasis, Invasive; Candidemia
Interventions: Drug: Isavuconazole; Drug: Caspofungin; Drug: Voriconazole
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Basilea Pharmaceutica
Recruiting - verified May 2012 - Conditions: Invasive Fungal Infection; Aspergillosis
Interventions: Drug: Isavuconazole; Drug: Voriconazole
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Basilea Pharmaceutica
Recruiting - verified May 2012 - Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Kidney Neoplasms
Interventions: Drug: Sunitinib malate; Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Neoplasms, Breast
Intervention: Drug: lapatinib + capecitabine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
 |
Join Clinical Trials that are Held in Beijing, China |
Clinical Trial Locations 